Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

@article{Hecht2016LapatinibIC,
  title={Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.},
  author={Joel Randolph Hecht and Yung-jue Bang and Shukui Qin and Hyun Cheol Chung and Jianming M Xu and Joon Oh Park and Krzysztof G Jeziorski and Yaroslav Shparyk and Paulo Marcelo Gehm Hoff and Alberto F Sobrero and Pamela Salman and Jin Li and Svetlana A. Protsenko and Zev A. Wainberg and Marc Buyse and Karen Afenjar and Vincent Hou{\'e} and Agathe Garcia and Tomomi Kaneko and Yingjie Huang and Saba Khan-Wasti and Sergio L. Santillana and Michael F Press and Dennis Slamon},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2016},
  volume={34 5},
  pages={443-51}
}
PURPOSE To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced gastroesophageal adenocarcinoma. PATIENTS AND METHODS Patients with HER2-positive advanced gastroesophageal adenocarcinoma were randomly assigned at a one-to-one ratio to CapeOx plus lapatinib 1,250 mg or placebo daily. Primary end point was overall survival (OS) in patients with centrally… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 14 times over the past 90 days. VIEW TWEETS
72 Citations
22 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 72 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: A randomised placebo-controlled trial

  • J Zheng, T de Guia, J Wang-Jairaj
  • Curr Med Res Opin 31:1191-1200,
  • 2015

Similar Papers

Loading similar papers…